Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases-Reference-Cited by-同舟云学术

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

Published:2020-07-15 Issue:19 Volume:63 Page:10773-10781
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Nagle Advait¹^ORCID,Biggart Agnes¹,Be Celine²,Srinivas Honnappa²,Hein Andreas²,Caridha Diana³,Sciotti Richard J.³,Pybus Brandon³,Kreishman-Deitrick Mara³,Bursulaya Badry¹,Lai Yin H.¹,Gao Mu-Yun¹,Liang Fang¹,Mathison Casey J. N.¹^ORCID,Liu Xiaodong¹,Yeh Vince¹,Smith Jeffrey¹,Lerario Isabelle¹,Xie Yongping¹,Chianelli Donatella¹,Gibney Michael¹,Berman Ashley¹,Chen Yen-Liang⁴,Jiricek Jan⁴,Davis Lauren C.¹,Liu Xianzhong¹,Ballard Jaime¹,Khare Shilpi¹,Eggimann Fabian Kurt²,Luneau Alexandre²,Groessl Todd¹,Shapiro Michael¹,Richmond Wendy¹,Johnson Kevin¹,Rudewicz Patrick J.⁴,Rao Srinivasa P. S.⁴^ORCID,Thompson Christopher⁵,Tuntland Tove¹,Spraggon Glen¹,Glynne Richard J.¹,Supek Frantisek¹,Wiesmann Christian²,Molteni Valentina¹^ORCID

Affiliation:

1. Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California 92121, United States

2. Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland

3. Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States

4. Novartis Institute of Tropical Diseases, Emeryville, California 94608, United States

5. Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, United States

Funder

Wellcome Trust

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00499

Reference18 articles.

1. Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis

2. Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India

3. Chemotherapeutics of visceral leishmaniasis: present and future developments

4. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

5. Antimony Toxicity

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural analysis and shape-based identification of novel inhibitors targeting the Trypanosoma cruzi proteasome;International Journal of Biological Macromolecules;2024-10

2. Investigational new drugs for the treatment of leishmaniasis;Expert Opinion on Investigational Drugs;2024-09-10

3. Clickable Probes for Pathogen Proteasomes: Synthesis and Applications;ACS Omega;2024-08-02

4. Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria;Cell Chemical Biology;2024-08

5. Functional characterization of Cullin-1-RING ubiquitin ligase (CRL1) complex in Leishmania infantum;PLOS Pathogens;2024-07-17